Advanced search

Combine gene, variant, phenotype, region and year filters

Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.

Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
About your search

SLCO1B1 and dyslipidemia are reported together in 1 article.

HGNC
HGNC:10959
15articles
15mentions
4variants with confirmed gene link
Most co-reported phenotypes (articles)
Reported variants (articles · ClinVar status)
Phenotype

Dyslipidemia

338articles
338mentions
12co-reported genes shown
Most co-reported genes (articles)

Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.

Publications

1 records shown · first 60

Unveiling hidden risks: pharmacogenetic insights from a cross-sectional study of statin therapy in the Indian population.

PMID 40489054 | DOI 10.1007/s43440-025-00746-1 · Pharmacological reports : PR · 2025 · 6 validated mentions
TypeEntitySource evidenceConfidenceExtractor
geneSLCO1B1“Hence, we conducted a population-level screening for pharmacogenetic determinants of statin therapy, particularly Solute Carrier Organic Anion Transporter Family Member 1B1 (SLCO1B1) and ATP-binding cassette sub-family G member 2 (ABCG2).”0.98hgnc_dict_v1
phenotypedyslipidemia“BACKGROUND: Statin usage has increased significantly in India due to the very high incidence of dyslipidemia, however, approximately 18% of the population is at risk for statin-induced myopathy.”0.98phenotype_alias_lexicon_v2
geneABCG2“Hence, we conducted a population-level screening for pharmacogenetic determinants of statin therapy, particularly Solute Carrier Organic Anion Transporter Family Member 1B1 (SLCO1B1) and ATP-binding cassette sub-family G member 2 (ABCG2).”0.98hgnc_dict_v1
phenotypecongenital myopathy“BACKGROUND: Statin usage has increased significantly in India due to the very high incidence of dyslipidemia, however, approximately 18% of the population is at risk for statin-induced myopathy.”0.93phenotype_alias_lexicon_v2